Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

Table 2 Hazard ratios with 95% confidence intervals and levels of significance for stopping treatment

All reasons	HR (95% CI)	Level of significance
Unadjusted infliximab vs. etanercept	2.37 (1.91; 2.93)	p < 0.001
^aInfliximab vs. etanercept	2.92 (2.32; 3.69)	p < 0.001
^bMonotherapy vs. MTX	1.82 (1.45; 2.29)	p < 0.001
^bOther DMARD vs. MTX	1.45 (1.12; 1.87)	p < 0.010
^bMonotherapy vs. other DMARD	1.22 (0.94; 1.61)	p = 0.127
All reasons, time-dependent Cox regression analysis	HR (95% CI)	Level of significance
^aInfliximab vs. etanercept	2.83 (2.27; 3.54)	p < 0.001
^bMonotherapy vs. MTX	1.48 (1.19; 1.85)	p < 0.001
^bOther DMARD vs. MTX	1.33 (1.08; 1.55)	p = 0.017
^bMonotherapy vs. other DMARD	1.10 (0.86; 1.40)	p = 0.448
Adverse events	HR (95% CI)	Level of significance
^bMonotherapy vs. MTX	2.14 (1.61; 2.84)	p < 0.001
^bOther DMARD vs. MTX	1.75 (1.28; 2.04)	p = 0.001
^bMonotherapy vs. other DMARD	1.23 (0.88; 1.71)	p = 0.231
Treatment failure	HR (95% CI)	Level of significance
^bMonotherapy vs. MTX	1.31 (0.86; 1.99)	p = 0.215
^bOther DMARD vs. MTX	1.07 (0.66; 1.73)	p = 0.782
^bMonotherapy vs. other DMARD	1.22 (0.72; 2.06)	p = 0.454

^aAlso adjusted for differences in concomitant disease-modifying antirheumatic drugs (DMARDs). ^bAlso adjusted for differences in tumour necrosis factor-blocking treatment. The first row contains unadjusted data, whereas the remaining data were adjusted for differences in age, gender, year of treatment initiation, 28-joint disease activity score (DAS28), health assessment questionnaire (HAQ) score, disease duration, previous DMARDs, and C-reactive protein (CRP) level. Data presented in the second section use HAQ score, DAS28, and CRP level as time-dependent covariates. CI, confidence interval; HR, hazard ratio; MTX, methotrexate.

ISSN: 1478-6362